Clover cancels AIM listing
Thursday, 19 January, 2006
Sydney-based Clover (ASX:CLV) has applied to the London Stock Exchange to cancel its listing on the Alternative Investment Market (AIM).
The cancellation is expected to take effect from February 16.
Clover's board felt that the costs associated with maintaining a dual listing on AIM and the ASX outweighed any benefits gained and the company will not be looking to raise new capital on AIM in the foreseeable future. All shareholdings registered in the UK on AIM will be automatically transferred following the delisting and will remain tradable as ordinary shares on the ASX.
Cartherics and Catalent announce enhanced partnership
To support immune cell therapy products for the treatment of cancer and endometriosis, Australian...
Alliance seeks to boost regional capacity in clinical trials
Launched this week, the Barwon Health–Deakin University Clinical Trials Alliance is...
Lipid science receives new Australia-led online hub
The Lipid Network launched this month to build links between researchers, clinicians and industry...
